3-(3-cyclopropane substituted phenyl-4-thiazolinone)-N-arylbenzamide compounds and applications
By developing 3-(3-cyclopropane-substituted phenyl-4-thiazolinone)-N-arylbenzamide compounds, the existing osteosarcoma treatment methods have solved the shortcomings of high metastasis and recurrence rates, and achieved It has important therapeutic significance for effective inhibition of osteosarcoma cells.
Patent Information
- Application Number
- CN202010972804.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-09-16
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing osteosarcoma treatment methods have limited effect on osteosarcoma patients with high metastasis and recurrence rates, and targeted treatment has not yet effectively improved survival.
A 3-(3-cyclopropane-substituted phenyl-4-thiazolinone)-N-arylbenzamide compound was developed, and the compound was prepared by synthetic methods and used to inhibit the proliferation of tumor cells. , migration, infiltration, metastasis and recurrence, promote tumor cell apoptosis.
This compound has shown significant inhibitory activity on tumor cells such as osteosarcoma, colorectal cancer, and leukemia, and has potential application value in the treatment of osteosarcoma and other related diseases.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of synthetic medicine and biomedicine, and mainly relates to a 3-(3-cyclopropane substituted phenyl-4-thiazolinone)-N-arylbenzamide compound and its preparation and application. Background Art
[0002] Osteosarcoma, also known as osteosarcoma, is a common malignant bone tumor that occurs in adolescents or children under the age of 20 (Link MP: Osteosarcoma in adolescents and young adults: new developments and controversies. Commentary on the use of presurgical chemotherapy. Cancer Treat Res 62: 383-385, 1993.). According to epidemiological studies of osteosarcoma, it is the most common bone malignancy in children, accounting for about 5% of pediatric tumors. Osteosarcoma is still a disease with a high mortality rate among malignant tumors in children and adolescents, second only to lymphoma and brain cancer, but early detection and timely treatment have greatly improved the survival rate of the disease.
[0003] Treatment methods for different types of osteosarcoma usually use combined medication after surgery. It is worth noting that the cancer metastasis rate of osteosarcoma patients is as high as 80%. Among patients with metastasis, 90% are lung metastases. The recurrence rate is 20-30%, and recurrence is possible in situ or in situ tissues. And the survival rate after recurrence has not improved in the past few decades, despite the adjustment of increasing the dose, changing the number of times, and combining multiple chemotherapy drugs.
[0004] At present, the research on therapeutic targets for osteosarcoma mainly focuses on the cell surface receptor tyrosine kinase family (PTKs) and intracellular signaling targets. For these targets, the main therapeutic drugs are divided into three categories: 1) immunomodulators; 2) receptor tyrosine kinase inhibitors; 3) intracellular signaling pathway inhibitors. In addition, new targets and treatment options for osteosarcoma include NK-kB ligands, folic acid inhibitors, etc., but they are all in the experimental research stage. Summary of the invention
[0005] The inventors have noticed that in previous literature reports, compounds with a thiazolinone skeleton structure have various pharmacological activities, such as the compound represented by formula (II) having anti-inflammatory activity and the compound represented by formula (III) having anti-AIDS activity:
[0006]
[0007] Prior to the present invention, there were no reports on the evaluation of osteosarcoma cell activity test for this type of framework. The inventors have discovered and proposed that this framework compound may produce a series of new compound molecules with significant structure and activity, which may provide a new source of compounds for biological activity screening.
[0008] The present invention provides a 3-(3-cyclopropane substituted phenyl-4-thiazolinone)-N-arylbenzamide compound or a pharmaceutically acceptable salt thereof, the structure of which is shown in formula (I);
[0009]
[0010] in,
[0011] Ar is aryl, aromatic heterocycle, alkyl-substituted aryl, halogen-substituted aryl, alkyl-substituted heteroaryl, halogen-substituted heteroaryl, trifluoromethyl-substituted aryl, nitro-substituted aryl, decalinyl, furanyl, alkenyl, alkynyl, diphenylalkyl, di(4-bromophenyl)alkyl, trifluoromethyl-substituted heteroaryl, nitro-substituted heteroaryl; wherein the aromatic heterocycle and heteroaryl are selected from indole, benzotriazole, thiophene, furan, pyrrole, bislactam, piperazine, imidazole, oxazole, pyrazine, etc.;
[0012] R 1 is halogen, alkoxy, alkyl, nitro, cyano, trifluoromethyl, phenyl, hydrogen, etc.;
[0013] R 2 is alkyl or hydrogen, etc.;
[0014] R 3 It is halogen, alkoxy, alkyl, cycloalkyl, nitro, cyano, trifluoromethyl, phenyl, hydrogen, etc.
[0015] n=0;1;2;3;4;5;6.
[0016] Preferably,
[0017] Ar is aryl, aromatic heterocycle, C1-C10 alkyl substituted aryl, halogen substituted aryl, C1-C10 alkyl substituted heteroaryl, halogen substituted heteroaryl, trifluoromethyl substituted aryl, nitro substituted aryl, naphthylmethyl, furanyl, allyl, propargyl, diphenylmethyl, di(4-bromophenyl)methyl, trifluoromethyl substituted heteroaryl, nitro substituted heteroaryl; wherein the aromatic heterocycle and heteroaryl are selected from indole, benzotriazole, thiophene, furan, pyrrole, bislactam, piperazine, imidazole, oxazole, pyrazine;
[0018] R 1 is halogen, C1-C10 alkoxy, methyl, ethyl, isopropyl, nitro, cyano, trifluoromethyl, phenyl, hydrogen;
[0019] R 2 is methyl or hydrogen;
[0020] R 3 It is halogen, C1-C10 alkoxy, methyl, ethyl, isopropyl, cyclopropyl, nitro, cyano, trifluoromethyl, phenyl, or hydrogen.
[0021] n=1;2;3;4;5;6.
[0022] The 3-(3-cyclopropane substituted phenyl-4-thiazolinone)-N-arylbenzamide compound or pharmaceutically acceptable salt thereof of the present invention comprises:
[0023] 3-(3-(4-cyclopropylphenyl)-4-thiazolinone)-N-(4-phenylethyl)benzamide;
[0024] 3-(3-(4-cyclopropylphenyl)-4-thiazolinone)-N-(4-phenylpropyl)benzamide;
[0025] 3-(3-(2-cyclopropylphenyl)-4-thiazolinone)-N-(4-phenylbutyl)benzamide;
[0026] 3-(3-(2-cyclopropylphenyl)-4-thiazolinone)-5-fluoro-N-(4-phenylbutyl)benzamide;
[0027] 3-(3-(2-cyclopropylphenyl)-4-thiazolinone)-5-methyl-N-(4-phenylbutyl)benzamide;
[0028] 3-(3-(2-cyclopropylphenyl)-4-thiazolinone)-N-(4-(4-chloro)phenylbutyl)benzamide;
[0029] 3-(3-(2-cyclopropylphenyl)-4-thiazolinone)-N-(4-(4-fluoro)phenylbutyl)benzamide;
[0030] 3-(3-(2-cyclopropylphenyl)-4-thiazolinone)-5-methyl-N-(4-(4-chloro)-phenylbutyl)benzamide;
[0031] 3-(3-(3-cyclopropylphenyl)-4-thiazolinone)-N-(4-phenylbutyl)benzamide;
[0032] 3-(3-(3-cyclopropylphenyl)-4-thiazolinone)-5-fluoro-N-(4-phenylbutyl)benzamide;
[0033] 3-(3-(3-cyclopropylphenyl)-4-thiazolinone)-5-methyl-N-(4-phenylbutyl)benzamide;
[0034] 3-(3-(3-cyclopropylphenyl)-4-thiazolinone)-N-(4-(4-chloro)phenylbutyl)benzamide;
[0035] 3-(3-(3-cyclopropylphenyl)-4-thiazolinone)-N-(4-(4-fluoro)phenylbutyl)benzamide;
[0036] 3-(3-(3-cyclopropylphenyl)-4-thiazolinone)-5-methyl-N-(4-(4-chloro)-phenylbutyl)benzamide;
[0037] 3-(3-(4-cyclopropylphenyl)-4-thiazolinone)-N-(4-phenylbutyl)benzamide;
[0038] 3-(3-(4-cyclopropylphenyl)-4-thiazolinone)-5-fluoro-N-(4-phenylbutyl)benzamide;
[0039] 3-(3-(4-cyclopropylphenyl)-4-thiazolinone)-5-methyl-N-(4-phenylbutyl)benzamide;
[0040] 3-(3-(4-cyclopropylphenyl)-4-thiazolinone)-5-methyl-N-(4-(4-chloro)-phenylbutyl)benzamide;
[0041] 3-(3-(4-cyclopropylphenyl)-4-thiazolinone)-N-(4-(4-chloro)phenylbutyl)benzamide;
[0042] 3-(3-(4-cyclopropylphenyl)-4-thiazolinone)-N-(4-(4-fluoro)phenylbutyl)benzamide;
[0043] 3-(3-phenyl-4-thiazolinone)-5-cyclopropane-N-(4-phenylbutyl)benzamide;
[0044] 3-(3-(3-cyclopropylphenyl)-4-thiazolinone)-N-(4-(N-pyrazolyl)butyl)-benzamide;
[0045] 3-(3-(3-cyclopropylphenyl)-4-thiazolinone-yl)-N-(4-(N-indolyl)butyl)-benzamide;
[0046] 3-(3-(4-cyclopropylphenyl)-4-thiazolinone)-N-5-methyl-(4-(N-pyrazolyl)butyl)benzamide;
[0047] 3-Cyclopropyl-5-(3-(2-methoxyphenyl)-4-thiazolinone)-N-(4-phenylbutyl)benzamide;
[0048] 3-Cyclopropyl-5-(3-(3-methoxyphenyl)-4-thiazolinone)-N-(4-phenylbutyl)benzamide;
[0049] 3-Cyclopropyl-5-(3-(4-methoxyphenyl)-4-thiazolinone-yl)-N-(4-phenylbutyl)benzamide.
[0050] The present invention also provides an acid addition salt formed by the 3-(3-cyclopropane substituted phenyl-4-thiazolinone)-N-arylbenzamide compound and an acid; wherein the acid is hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, acetic acid, salicylic acid, tartaric acid, lactic acid, citric acid, methanesulfonic acid, p-toluenesulfonic acid, maleic acid, pyruvic acid or succinic acid.
[0051] The present invention also provides a pharmaceutical composition, which comprises the 3-(3-cyclopropane substituted phenyl-4-thiazolinone)-N-arylbenzamide compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0052] Wherein, the pharmaceutical composition is formulated into pills, capsules, creams, gels, excipients, injectable fluids, aerosols, syrups or transdermal patches, etc.
[0053] The present invention also proposes the use of the 3-(3-cyclopropane substituted phenyl-4-thiazolinone)-N-arylbenzamide compound or pharmaceutically acceptable salt, or pharmaceutical composition in the preparation of drugs for preventing and / or treating tumors.
[0054] The 3-(3-cyclopropane substituted phenyl-4-thiazolinone)-N-arylbenzamide compounds are used to inhibit the proliferation, growth, migration, infiltration, metastasis and recurrence of tumor cells, or promote the apoptosis of tumor cells.
[0055] Among them, the tumors include osteosarcoma, colorectal cancer, leukemia, lung cancer, etc.
[0056] The osteosarcoma cells include SJSA-1 osteosarcoma cells, MNNG / HOS osteosarcoma cells, U-2-OS osteosarcoma cells, MG63 osteosarcoma cells, HOS osteosarcoma cells, and 143B osteosarcoma cells.
[0057] The lung cancer cells include A549 lung cancer cells.
[0058] The leukemia cells include Jurkat leukemia cells.
[0059] The colorectal cancer cells include HCT116 colorectal cancer cells.
[0060] The present invention also provides a method for synthesizing a 3-(3-cyclopropane substituted phenyl-4-thiazolinone)-N-arylbenzamide compound or a pharmaceutically acceptable salt thereof as shown in formula (I). When the cyclopropane group on the benzene ring is at the meta position of the amine group, the method for synthesizing a 3-(3-cyclopropane substituted phenyl-4-thiazolinone)-N-arylbenzamide compound or a pharmaceutically acceptable salt thereof as shown in formula (I) specifically comprises the following steps, including the following four reaction formulas (A), (B), (C), and (D):
[0061]
[0062] In the first step, m-bromoaniline is coupled with cyclopropaneboronic acid under the catalysis of palladium acetate / cyclohexylphosphine system to obtain m-cyclopropane aniline.
[0063]
[0064] In the second step, p-cyclopropylaniline (10 mmol, 1.0 eq) and methyl 3-formaldehyde benzoate (10 mmol, 1.0 eq) were reacted under toluene reflux conditions for 30 minutes to generate the corresponding imine compound. The reaction system was then cooled to room temperature, and thioethanol (10 mmol, 1.0 eq) was added to continue refluxing. After reacting for 5 hours, the reaction was cooled to room temperature, and the reaction was monitored by spot plate to complete. The ester compound was then separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1 to 1:1).
[0065]
[0066] In the third step, the ester compound (5 mmol, 1.0 eq) obtained in the second step and LiOH (5.25 mmol, 1.05 eq) were reacted in a methanol: water (4:1) solvent at room temperature for 20 hours. The substrate was completely consumed by spot plate monitoring. After the reaction was completed, the methanol in the solvent was removed by rotary evaporation, and the remaining reaction solution was poured into 50 mL of water, and 3N HCl was added dropwise to acidify it. The pH was monitored with pH test paper until pH = 1. The organic phase was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and then rotary evaporated to obtain the carboxylic acid product.
[0067]
[0068] In the fourth step, the carboxylic acid product (1.5mmol, 1.0eq) obtained in the third step and 1-hydroxybenzotriazole (i.e., HOBt, 3.0mmol, 2.0eq) were dissolved in 20mL tetrahydrofuran, and N,N-diisopropylethylamine (DIPEA, 4.5mmol, 3.0eq) was added under ice bath conditions. After stirring for 20 minutes, the compound phenylbutylamine was added and continued to stir for 10 minutes. Subsequently, the condensing agent 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI, 3mmol, 2.0eq) was added in batches. After two hours of reaction, the plate was monitored and the raw materials were completely consumed. An appropriate amount of saturated sodium bicarbonate was added to the reaction solution in sequence, washed with saturated brine, and extracted with ethyl acetate three times. The crude product obtained by rotary evaporation was finally obtained by column chromatography (petroleum ether: ethyl acetate = 3:1 to 1:1) to obtain the target product.
[0069] When the cyclopropane group on the benzene ring is in the para (or ortho) position to the amine group, the synthesis method of the 3-(3-cyclopropane substituted phenyl-4-thiazolinone)-N-arylbenzamide compound or the pharmaceutically acceptable salt thereof as shown in formula (I) specifically comprises the following steps, including the following four reaction formulas (E), (F), (G), and (H):
[0070]
[0071] First, as shown in reaction formula (E), p-(or o-) nitrobromobenzene and cyclopropaneboric acid are coupled under the catalysis of palladium acetate / cyclohexylphosphine system to obtain 4-(or 2-) cyclopropane nitrobenzene. Then, the nitro group is reduced to an amine group using excess iron powder and acetic acid to obtain a p-(or o-) cyclopropane aniline product, and the target compound is finally obtained by referring to reaction formulas (B), (C), and (D).
[0072] Among them, in reaction formula (A), (B), (C), (D) and reaction formula (E), Ar, R 1 , R 2 The same as defined in formula (I).
[0073] The beneficial effect of the present invention is that: the present invention discloses a 3-(3-cyclopropane substituted phenyl-4-thiazolinone)-N-arylbenzamide compound or a pharmaceutically acceptable salt thereof, which has an inhibitory activity on tumor cells and can be used to treat osteosarcoma, colorectal cancer, leukemia and other related diseases, and has important significance in the study of tumor diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0074] Figure 1 The product Cyclo-1 obtained in Example 1 1 H NMR ( Figure 1 A) and 13 C NMR ( Figure 1B) Schematic diagram.
[0075] Figure 2 The product Cyclo-2 obtained in Example 2 1 H NMR ( Figure 2 A) and 13 C NMR ( Figure 2 B) Schematic diagram.
[0076] Figure 3 The product Cyclo-3 obtained in Example 3 1 H NMR ( Figure 3 A) and 13 C NMR ( Figure 3 B) Schematic diagram.
[0077] Figure 4 The product Cyclo-4 obtained in Example 4 1 H NMR ( Figure 4 A) and 13 C NMR ( Figure 4 B) Schematic diagram.
[0078] Figure 5 The product Cyclo-5 obtained in Example 5 1 H NMR ( Figure 5 A) and 13 C NMR ( Figure 5 B) Schematic diagram.
[0079] Figure 6 The product Cyclo-6 obtained in Example 6 1 H NMR ( Figure 6 A) and 13 C NMR ( Figure 6 B) Schematic diagram.
[0080] Figure 7 The product Cyclo-7 obtained in Example 7 1 H NMR ( Figure 7 A) and 13 C NMR ( Figure 7 B) Schematic diagram.
[0081] Figure 8 The product Cyclo-8 obtained in Example 8 1 H NMR ( Figure 8 ).
[0082] Fig. 9 The product Cyclo-9 obtained in Example 9 is 1 H NMR ( Fig. 9 A) and 13 C NMR ( Fig. 9 B) Schematic diagram.
[0083] Fig.10 The product Cyclo-10 obtained in Example 10 1 H NMR ( Fig.10 A) and 13 C NMR ( Fig.10 B) Schematic diagram. DETAILED DESCRIPTION
[0084] The present invention is further described in detail in conjunction with the following specific embodiments and drawings, and the protection content of the present invention is not limited to the following embodiments. Without departing from the spirit and scope of the inventive concept, changes and advantages that can be thought of by those skilled in the art are included in the present invention and are protected by the attached claims.
[0085] The preparation methods of the compounds in the following examples of the present invention refer to the preparation of the compound represented by formula (I) mentioned above. Determination method: low-resolution mass spectrometry (molecular weight) and nuclear magnetic resonance instrument (hydrogen spectrum and carbon spectrum).
[0086] Embodiment 1:
[0087]
[0088] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Figure 1 As shown:
[0089] 1 H NMR(400MHz,Chloroform-d)δ7.78(d,J=6.4Hz,1H),7.57(d,J=7.8Hz,1H),7.42(t, J=6.2Hz,1H),7.29–7.05(m,9H),6.71–6.60(m,1H),6.08(s,1H),3.92–3.75(m,3H),3.73– 3.59(m,3H),3.40–3.20(m,2H),2.91(s,1H),2.57(q,J=7.0Hz,2H),1.56(dt,J=24.2Hz,7.6 Hz,4H).
[0090] 13C NMR (101MHz, CDCl3) δ171.04,169.55,166.73,145.51,141.98,140.35,137.18,135.30, 129.81,129.14,128.41,127.10,124.75,123.28,122.76,65.36,40.02,35.47,33.47,29.17,28.68,15.29,9.42.
[0091] Embodiment 2:
[0092]
[0093] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Figure 2 As shown:
[0094] 1 H NMR(400MHz,Chloroform-d)δ7.70(s,1H),7.62(d,J=7.2Hz,1H),7.43(s,1H),7.39– 7.17(m,5H),7.04(t,J=7.7Hz,1H),6.79(d,J=16.8Hz,4H),6.18(s,1H),6.02(s,1H),4.12( t,J=6.2Hz,3H),3.91(d,J=15.9Hz,1H),3.79(d,J=15.7Hz,1H),3.35(d,J=5.6Hz,3H),1.94– 1.79(m,4H),1.57–1.46(m,4H),0.81(d,J=7.8Hz,3H),0.51–0.43(m,2H).
[0095] 13 C NMR(100MHz,Chloroform-d)δ170.02,165.74,144.46,139.27,138.18,136.18,134.13, 128.79,128.29,128.06,127.99,126.35,124.99,123.70,122.27,121.76,1 04.55,64.37,50.22,38.58,32.44,28.68,27.00,24.98,14.26,8.46,8.40.
[0096] Embodiment 3:
[0097]
[0098] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Figure 3 As shown:
[0099] 1 H NMR(400MHz,Chloroform-d)δ7.70(t,J=1.8Hz,1H),7.59(dt,J=7.6Hz,1.5Hz,1H), 7.40(dt,J=7.8Hz,1.4Hz,1H),7.34–7.24(m,4H),7.18(td,J=7.4Hz,6.8Hz,1.7Hz,4H),6.9 9(d,J=8.5Hz,2H),6.91(d,J=8.6Hz,2H),6.31(t,J=5.8Hz,1H),6.06(d,J=1.6Hz,1H),3.95 (dd,J=15.8Hz,1.7Hz,1H),3.83(d,J=15.8Hz,1H),3.48–3.32(m,2H),2.64(t ,J=7.4Hz,3H),1.91(s,1H),0.98–0.80(m,2H),0.58(dd,J=4.8Hz,1.9Hz,2H).
[0100] 13 C NMR (101MHz, CDCl3) δ171.05,166.72,143.41,142.04,140.35,135.33,134.38,129.76, 129.11,128.38,127.21,126.41,125.93,125.88,125.65,65.29,40.00,35.49,33.43,29.15,28.72,15.04,9.46,9.36.
[0101] Embodiment 4:
[0102]
[0103] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Figure 4 As shown:
[0104] 1H NMR(400MHz,Chloroform-d)δ7.64(d,J=3.7Hz,1H),7.49(dd,J=22.7Hz,7.6Hz, 1H),7.32(dd,J=20.4Hz,7.7Hz,2H),7.13(d,J=8.1Hz,3H),6.98(d,J=8.1Hz,4H),6.81(s,1 H),5.99(s,1H),4.11(d,J=6.9Hz,0H),3.99(d,J=6.9Hz,1H),3.27(d,J=6.0Hz,3H),2.49(t, J=6.6Hz,5H),1.62(d,J=6.9Hz,2H),1.17(s,1H),0.77(d,J=7.5Hz,3H).
[0105] 13 C NMR (101MHz, CDCl3) δ173.82,166.74,145.41,140.50,137.64,135.31,135.00,131.47, 130.38,129.77,129.33,128.94,128.41,127.10,124.60,123.36,122.83,122. 28,63.29,42.72,41.80,39.87,34.78,29.06,28.57,19.98,19.22,15.32,9.51.
[0106] Embodiment 5:
[0107]
[0108] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Figure 5 As shown:
[0109] 1H NMR (400MHz, Chloroform-d) δ7.67 (s, 1H), 7.56 (dd, J = 17.1Hz, 7.5Hz, 1H), 7.42 (d, J =23.8Hz,1H),7.17(d,J=7.4Hz,3H),7.04(d,J=8.1Hz,1H),6.99(d,J=8.1Hz,1H),6.92(t, J=9.0Hz,2H),6.13(s,1H),4.20(d,J=6.9Hz,0H),4.10(d,J=6.9Hz,0H),3.42(d,J=6.1Hz, 2H), 2.65 (t, J = 7.0Hz, 2H), 1.73 (d, J = 7.1Hz, 3H), 1.27 (d, J = 10.3Hz, 1H), 0.89 (s, 2H).
[0110] 13 C NMR (101MHz, CDCl3) δ173.78,166.74,143.11,142.01,130.35,129.32,129.17,129.02, 128.41,126.99,126.88,126.56,126.35,125.88,125.71,125.52,125.20, 42.68,41.78,39.98,35.48,29.17,28.70,20.15,19.31,15.02,9.41,9.30.
[0111] Embodiment 6:
[0112]
[0113] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Figure 6 As shown:
[0114] 1H NMR (400MHz, Chloroform-d) δ7.70 (s, 1H), 7.57 (d, J = 27.7Hz, 1H), 7.41 (dd, J = 18.6, 7.7Hz,1H),7.16(d,J=7.0Hz,4H),7.07(d,J=8.1Hz,1H),6.90(s,1H),6.80(d,J=12.1Hz, 2H),6.00(s,0H),4.19(d,J=6.9Hz,0H),4.09(d,J=6.9Hz,0H),3.39(d,J= 5.9Hz,2H),2.62(d,J=7.0Hz,3H),1.72(s,1H),1.33(s,1H),0.86(s,2H).
[0115] 13 C NMR (101MHz, CDCl3) δ173.81,166.75,145.42,142.04,140.81,139.56,137.66,135.38, 130.37,129.30,128.96,126.71,125.87,124.62,123.38,122.84,122.28,6 3.29,41.82,39.98,35.49,29.72,29.16,28.71,20.00,19.24,15.33,9.48.
[0116] Embodiment 7:
[0117]
[0118] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Figure 7 As shown:
[0119] 1 H NMR(400MHz,Chloroform-d)δ7.64(d,J=3.7Hz,1H),7.49(dd,J=22.7Hz,7.6Hz, 1H),7.32(dd,J=20.4Hz,7.7Hz,2H),7.13(d,J=8.1Hz,3H),6.98(d,J=8.1Hz,4H),6.81(s,1 H),5.99(s,1H),4.11(d,J=6.9Hz,0H),3.99(d,J=6.9Hz,1H),3.27(d,J=6.0Hz,3H),2.49(t, J=6.6Hz,5H),1.62(d,J=6.9Hz,2H),1.17(s,1H),0.77(d,J=7.5Hz,3H).
[0120] 13 C NMR (101MHz, CDCl3) δ173.82,166.74,145.41,140.50,137.64,135.31,135.00,131.47, 130.38,129.77,129.33,128.94,128.41,127.10,124.60,123.36,122.83,122. 28,63.29,42.72,41.80,39.87,34.78,29.06,28.57,19.98,19.22,15.32,9.51.
[0121] Embodiment 8:
[0122]
[0123] Nuclear Magnetic Resonance 1 H NMR spectrum Figure 8 As shown:
[0124] 1 H NMR (400MHz, Chloroform-d) δ7.95 (dd, J=3.2Hz, 1.6Hz, 1H), 7.94–7.84 (m, 1H), 7.69(s,1H),7.64–7.53(m,2H),7.50–7.40(m,3H),7.40–7.22(m,6H),7.19(s,1H),7.10–6.9 8(m,2H),6.92–6.73(m,3H),6.19(s,0H),6.04(d,J=7.0Hz,1H),5.96(d,J=11.9Hz,0H),4.23– 3.85(m,3H),3.49–3.19(m,1H),2.00–1.76(m,2H),1.79–1.56(m,4H),1.52(dd,J= 14.3Hz, 7.5Hz, 3H), 1.18 (s, 3H), 0.82 (dd, J=7.7Hz, 4.7Hz, 3H), 0.60–0.40 (m, 4H).
[0125] Embodiment 9:
[0126]
[0127] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Fig. 9 As shown:
[0128] 1H NMR (400MHz, Chloroform-d) δ7.61 (s, 1H), 7.46 (d, J = 7.4Hz, 1H), 7.37 (d, J = 7.3Hz, 1H),7.22(dd,J=16.0Hz,7.7Hz,6H),7.14(d,J=7.1Hz,3H),7.08(d,J=7.9Hz,1H),6.77(dd ,J=12.5Hz,8.7Hz,3H),6.69(t,J=7.4Hz,1H),6.17(s,1H),6.04(s,1H),3.91–3.76(m,2H), 3.71(s,3H),3.59(d,J=6.1Hz,2H),2.83(t,J=6.2Hz,3H).
[0129] 13 C NMR (101MHz, CDCl3) δ170.39,165.75,153.76,138.76,137.81,133.86,129.71,129.09, 128.68,127.78,127.70,126.24,125.61,125.49,124.13,119.86,111.07,63.29,54.69,40.16,34.58,32.11.
[0130] Embodiment 10:
[0131]
[0132] Nuclear Magnetic Resonance 1 H NMR, 13 C NMR spectrum Fig.10 As shown:
[0133] 1 H NMR (400MHz, Chloroform-d) δ7.61 (s, 1H), 7.42 (d, J = 7.5Hz, 1H), 7.37 (d, J = 7.5Hz, 1H),7.18(d,J=5.0Hz,4H),7.13–7.03(m,5H),6.80(d,J=7.6Hz,1H),6.74(d,J=8.2Hz,1H),6 .66(t,J=7.4Hz,1H),6.32(s,1H),6.03(s,1H),3.81(q,J=15.6Hz,4H),3.70(s,3H),3.32(d,J =6.0Hz,3H),2.59(t,J=7.2Hz,3H),1.89–1.74(m,3H).
[0134] 13C NMR (101MHz, CDCl3) δ171.52,166.72,154.80,141.47,139.72,134.86,130.60,130.14, 129.74,128.68,128.54,128.39,127.30,126.61,126.07,125.18,120.87,112.09,64.37,55.74,39.87,33.48,33.16,31.01.
[0135] Embodiment 11:
[0136] Antitumor activity test
[0137] 1. Inoculation of cells:
[0138] 1) A single cell suspension was prepared using 1640 culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 SJSA-1 osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0139] 2) A single cell suspension was prepared using DMEM culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 MNNG / HOS osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0140] 3) A single cell suspension was prepared using McCoy'5A culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 U-2-OS osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0141] 4) A single cell suspension was prepared using DMEM culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 MG63 osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0142] 5) A single cell suspension was prepared using 1640 culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 HOS osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0143] 6) A single cell suspension was prepared using 1640 culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 143B osteosarcoma cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0144] 7) A single cell suspension was prepared using 1640 culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 A549 lung cancer cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0145] 8) A single cell suspension was prepared using 1640 culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 Jurkat leukemia cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0146] 9) A single cell suspension was prepared using 1640 culture medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and 2500 HCT116 colorectal cancer cells were inoculated into a 96-well cell culture plate in each well, with a volume of 100 μl per well.
[0147] 2. Administration: The compounds of formula (I) synthesized in the aforementioned embodiments of the present invention (the 10 compounds Cyclo-1 to Cyclo-10 listed in Table 1, Table 2 and Table 3) were respectively prepared with DMSO to a stock solution with a final concentration of 25 mM, diluted to 1 uM with complete culture medium, and applied to cells, with three replicate wells set up.
[0148] 3. Cultivation: Cultivate in an incubator with 5% CO2 and 37°C saturated humidity for 72 hours.
[0149] 4. Color development: After 72 hours of culture, aspirate the culture medium, add 100 μl complete culture medium and 10 μl CCK8 to each well, and incubate at 37°C for 4 hours.
[0150] 5. Colorimetry: Select 620nm and 450nm wavelengths, measure the optical density (OD) value of each well on the microplate reader, and record the results.
[0151] 6. For the same well, the absorbance value at 450nm minus the absorbance value at 620nm (background absorbance value) is used as the final absorbance and is substituted into the following formula.
[0152] 7. Cell proliferation activity (%) = [A(drug added) - A(blank)] / [A(0 drug added) - A(blank)] × 100.
[0153] A (drug addition): absorbance of wells containing tumor cells, CCK solution (Cell Counting Kit-8, a rapid and highly sensitive detection reagent for cell proliferation and cytotoxicity based on WST-8 (chemical name: 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfonylbenzene)-2H-tetrazolyl monosodium salt)) and drug solution (drug solution refers to the DMSO solution of the compound sample to be tested)
[0154] A (blank): absorbance of wells with culture medium and CCK solution but no cells
[0155] A(0 drug addition): absorbance of the well with cells, CCK solution and no drug solution
[0156] 8. The experimental results show that: under the action of the compound of formula (I) of the present invention at a concentration of 1 μM, the survival rates of 6 subtypes of human osteosarcoma cell lines of each compound (the 10 compounds Cyclo-1 to Cyclo-10 listed in Table 1) are as shown in Table 1. This shows that among these 10 compounds, 4 compounds Cyclo-1, Cyclo-3, Cyclo-5, and Cyclo-6 showed good inhibitory activity on osteosarcoma cells 143B; 4 compounds Cyclo-1, Cyclo-3, Cyclo-6, and Cyclo-7 showed good inhibitory activity on osteosarcoma cells SJSA-1; 4 compounds Cyclo-1, Cyclo-3, Cyclo-5, and Cyclo-6 showed good inhibitory activity on osteosarcoma cells HOS; 5 compounds Cyclo-1, Cyclo-2, Cyclo-3, Cyclo-5, and Cyclo-6 showed good inhibitory activity on osteosarcoma cells MNNG / HOS; 7 compounds Cyclo-1, Cyclo-2, Cyclo-3, Cyclo-5, Cyclo-6, Cyclo-7, and Cyclo-8 showed very good inhibitory activity on osteosarcoma cells MG63.
[0157] Table 1
[0158]
[0159] 9. The experimental results show that: under the action of the compound of formula (I) of the present invention at a concentration of 1 μM, the survival rate of each compound (the 10 compounds Cyclo-1 to Cyclo-10 listed in Table 2) of the lung cancer cell line A549 is shown in Table 2. This shows that among these 10 compounds, 4 compounds Cyclo-1, Cyclo-3, Cyclo-6, and Cyclo-7 show good inhibitory activity against lung cancer cells A549.
[0160] Table 2
[0161]
[0162] 10. The experimental results show that: under the action of the compound of formula (I) of the present invention at a concentration of 1 μM, the survival rate of the leukemia cell line Jurkat of each compound (the 10 compounds Cyclo-1 to Cyclo-10 listed in Table 3) is shown in Table 3. This shows that among these 10 compounds, 7 compounds Cyclo-1, Cyclo-2, Cyclo-3, Cyclo-5, Cyclo-6, Cyclo-7, and Cyclo-8 show very good inhibitory activity on leukemia cells Jurkat.
[0163] Table 3
[0164]
[0165] 11. The experimental results show that: under the action of the compound of formula (I) of the present invention at a concentration of 1 μM, the survival rate of each compound (the 10 compounds Cyclo-1 to Cyclo-10 listed in Table 4) of colorectal cancer cells HCT116 is shown in Table 4. This shows that among these 10 compounds, 8 compounds Cyclo-1, Cyclo-2, Cyclo-3, Cyclo-4, Cyclo-5, Cyclo-6, Cyclo-7, and Cyclo-8 show very good inhibitory activity on colorectal cancer cells HCT116.
[0166] Table 4
[0167]
[0168] The protection content of the present invention is not limited to the above embodiments. Without departing from the spirit and scope of the inventive concept, changes and advantages that can be thought of by those skilled in the art are included in the present invention and are protected by the attached claims.
Claims
1. A 3-(3-cyclopropane-substituted phenyl-4-thiazolinone)- N -Arylbenzamide compounds or pharmaceutically acceptable salts thereof, characterized in that: Selected from the following: 3-(3-(3-cyclopropylphenyl)-4-thiazolinone)- N -(4-phenylbutyl)benzamide; 3-(3-(3-cyclopropylphenyl)-4-thiazolinone)- N -(4-(4-chloro)phenylbutyl)benzamide; 3-(3-(4-cyclopropanephenyl)-4-thiazolinone)- N -(4-phenylbutyl)benzamide; 3-(3-(4-cyclopropanephenyl)-4-thiazolinone)- N -(4-phenylethyl)benzamide; 3-(3-(4-cyclopropanephenyl)-4-thiazolinone)- N -(4-phenylpropyl)benzamide; 3-(3-(4-cyclopropanephenyl)-4-thiazolinone)- N -5-methyl-(4-(4-chloro)phenylbutyl)benzamide; 3-(3-(3-cyclopropylphenyl)-4-thiazolinone)- N -5-methyl-(4-(4-chloro)phenylbutyl)benzamide; 3-(3-(4-cyclopropanephenyl)-4-thiazolinone)- N -5-methyl-(4-phenylbutyl)benzamide; 3-(3-(3-cyclopropylphenyl)-4-thiazolinone)- N -5-methyl-(4-phenylbutyl)benzamide; 3-(3-(3-cyclopropylphenyl)-4-thiazolinone)- N -5-methyl-(4-( N -pyrazole)phenylbutyl)benzamide.
2. The 3-(3-cyclopropane-substituted phenyl-4-thiazolinone)- N -Arylbenzamide compounds or pharmaceutically acceptable salts thereof, characterized in that: The acid addition salt formed by the compound and an acid; wherein the acid is hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, acetic acid, salicylic acid, tartaric acid, lactic acid, citric acid, methanesulfonic acid, p-toluenesulfonic acid, maleic acid, pyruvic acid or succinic acid.
3. A pharmaceutical composition, characterized in that It contains the 3-(3-cyclopropane substituted phenyl-4-thiazolinone)- N - an aryl benzamide compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition according to claim 3, characterized in that The pharmaceutical composition is formulated as a pill, capsule, cream, gel, injectable fluid, aerosol, syrup or transdermal patch.
5. The 3-(3-cyclopropane substituted phenyl-4-thiazolinone)- N - Use of an arylbenzamide compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as claimed in claim 3 in the preparation of a drug for preventing and / or treating tumors, wherein: The tumor is osteosarcoma, colorectal cancer, or leukemia.
6. The use according to claim 5, characterized in that: The 3-(3-cyclopropane substituted phenyl-4-thiazolinone)- N -Arylbenzamide compounds or pharmaceutically acceptable salts, or pharmaceutical compositions are used to inhibit the proliferation, growth, migration, infiltration, metastasis and recurrence of tumor cells, or promote apoptosis of tumor cells.
7. The use according to claim 5, characterized in that: The osteosarcoma cells are SJSA-1 osteosarcoma cells, MNNG / HOS osteosarcoma cells, U-2-OS osteosarcoma cells, MG63 osteosarcoma cells, HOS osteosarcoma cells, and 143B osteosarcoma cells; the leukemia is Jurkat leukemia cells; and the colorectal cancer is HCT116.
